Researchers at the ImmunoSensation cluster of excellence at the University of Bonn have managed to do what many scientists dream of: together with researchers from the USA, they have patented new molecules that allow the immune system to be directed against tumor cells. The license has already given the University of Bonn a first payment – and the scientists also gained a share. An exemplary success within the biomedical research landscape in Germany.
The discovery comes from the ImmunoSensation cluster of excellence at the University of Bonn, one of the leading centers for immunology. Prof. Gunther Hartmann, Prof. Winfried Barchet and Dr. Thomas Zillinger, together with scientists from three American universities, identified a new molecule produced naturally in the body that allows a person’s own immune response to be oriented against tumor cells.
For the University of Bonn, PROvendis assumed the exclusive patent exploitation for the company Aduro Biotech based in the USA, which is now further developing the discovery until market maturity. With this patent, among other rights, Aduro Biotech managed to enter into a research and development cooperation with the pharma giant Novartis worth 750 million US dollars.
The immune system is often tricked by tumors, and the new treatment approach counteracts this. If the immune system identifies foreign genetic material (DNA) in a cell, an alarm is triggered and the defenses are immediately prepared for the possible intruder. This cry for help occurs via the signal protein STING. It sets a cascade of defense mechanisms in motion that detect and destroy altered body cells such as tumor cells. “We have found the molecular key to STING activation,” reports Dr. Winfried Barchet, professor for translational immunology at the German Center for Infection Research (DZIF) at University Hospital Bonn and member of the ImmunoSensation cluster of excellence.
A tiny molecular key activates the alarm button
This key is a tiny ring structure made up of just two nucleic acid components. These two components are linked to each other in a special way, called a 2’-5’ link. Until now, similar 3’-5’ linked molecules have been known for bacteria, although they display hardly any activity in people. “Only this special feature of the 2’-5’ link enables STING to be activated in people,” adds Dr. Thomas Zillinger, junior research group leader at the Institute for Clinical Chemistry and Clinical Pharmacology.
The discovery concerns a small molecule with a big effect. It allows a new signal path in the immune system to be controlled in a targeted way for the first time. “For us, this is a great scientific success that has led to top-class publications and is also considered one of the most groundbreaking new approaches for cancer immunotherapy,” says Prof. Hartmann, spokesman for the cluster of excellence and director of the Institute for Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn. Thanks to the acquisition of the license by the biotech company, the discovery is now being directly transferred into clinical development and is thus already reaching patients.
“Besides the prospect of better treatment for patients, it is not only the industry partners who are benefitting from this discovery, but also the University of Bonn and the scientists with inventor's rights to 30 per cent of the revenue,” says Dr. Wolfram Schleich, Manager Patents & Licenses at PROvendis GmbH, to welcome the deal. In the German university landscape, research results are often not protected and exploited as patients. According to the German patent office, only around 1.5 per cent of all patent registrations come from universities across the country. Schleich: “In many cases, research results lie dormant in the universities as inactive capital, although these could flow into the economic cycle of the knowledge society.”
Further discoveries in the pipeline
And that’s only the beginning of the success story: “A further discovery from the cluster of excellence recently achieved clinical development as cancer treatment. This shows once again: top immunological research at the ImmunoSensation cluster of excellence is spurring on clinical medicine,” Prof. Hartmann is convinced.
PROvendis drives forward technology transfer between science and business and works for universities and companies in the field of patent management and patent marketing. PROvendis GmbH is a subsidiary of the University of Bonn and a further 23 universities and, as a service provider, has been responsible for currently 30 universities and extramural research institutions since 2002. More information: http://www.provendis.info
Dr. Elisabeth Mettke
Press and Public Relations
ImmunoSensation: Cluster of Excellence
University of Bonn
Head of Marketing
Muelheim an der Ruhr/Germany
Johannes Seiler | idw - Informationsdienst Wissenschaft
'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS
New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.
But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...
Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.
The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...
Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters
Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...
Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).
Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
16.02.2018 | Information Technology
16.02.2018 | Health and Medicine
16.02.2018 | Physics and Astronomy